PUBLISHER: DelveInsight | PRODUCT CODE: 1116917
PUBLISHER: DelveInsight | PRODUCT CODE: 1116917
DelveInsight's, 'Idiopathic Pulmonary Fibrosis -Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis , historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The Idiopathic Pulmonary Fibrosis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Idiopathic Pulmonary Fibrosis market size from 2019 to 2032. The Report also covers current Idiopathic Pulmonary Fibrosis treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032
Idiopathic Pulmonary Fibrosis Overview
Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect middle-aged and older adults. It affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis), which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as 'Diffuse Parenchymal Lung Diseases,' which is characterized by a broader umbrella of 'Interstitial Lung Diseases (IDLs).
It is a form of interstitial lung disease, primarily involving the interstitium (the tissue and space around the air sacs of the lungs) and not directly affecting the airways or blood vessels. Many other kinds of interstitial lung disease can also cause inflammation and/or fibrosis, and these are treated differently.
Idiopathic Pulmonary Fibrosis Diagnosis
Careful evaluation of clinical, laboratory, X-ray data and high resolution computed tomography (HRCT), and at times lung biopsy material to make a confident diagnosis. This is usually done by a respiratory specialist in union with other specialists with interest in IPF. The diagnosis of IPF relies on the clinician to assimilate and correlate the clinical, laboratory, radiologic, and/or pathologic data.
There are several diagnostic tools available and the consensus guidelines have been well defined to identify IPF. Pulmonary function tests are performed to assess for restrictive lung disease which is characterized by decreased lung volumes (especially decreased forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity. When IPF is suspected, laboratory tests to exclude autoimmune disease are also performed. Chest imaging is like x-rays is done but when they are not detailed enough to confirm IPF. High-resolution CT (HRCT) of the chest is performed. Patients may also be referred to a surgeon for a lung biopsy under general anesthesia in some instances.
Continued in the report…..
Idiopathic Pulmonary Fibrosis Treatment
The therapeutic approach of IPF involves both non-pharmacological and pharmacological strategies. The goal of the treatment is to slow disease progression, reduce symptoms, prevent acute exacerbations, and prolong the survival. There are two anti-fibrotic agents ESBRIET (Roche) and OFEV (Boehringer Ingelheim) approved for use in IPF. Both drugs are known to slow the disease progression but do not significantly impact mortality.
Continued in the report…..
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by diagnosed prevalent cases of idiopathic pulmonary fibrosis, gender-specific diagnosed prevalent cases of idiopathic pulmonary fibrosis, age-specific diagnosed prevalent cases of idiopathic pulmonary fibrosis, and severity-specific diagnosed prevalent cases of idiopathic pulmonary fibrosis scenario of Idiopathic Pulmonary Fibrosis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Key Findings
The epidemiology segment also provides the Idiopathic Pulmonary Fibrosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The drug chapter segment of the Idiopathic Pulmonary Fibrosis report encloses the detailed analysis of Idiopathic Pulmonary Fibrosis marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Idiopathic Pulmonary Fibrosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.
Idiopathic Pulmonary Fibrosis Marketed Drugs
ESBRIET (Pirfenidone): Hoffmann-La Roche Ltd
ESBRIET is an orally administered, anti-inflammatory and antifibrotic prescription medicine used for the treatment of mild and moderate cases of IPF in adults. The drug acts by reducing the amount of lung fibrosis by blocking secretions responsible for excessive collagen production and prolonging the patient's survival by slowing the progression of the disease.
OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
OFEV is a prescription drug for the treatment of IPF in adults. Nintedanib is the key ingredient and is a kinase inhibitor that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs).
Products detail in the report…
Idiopathic Pulmonary Fibrosis Emerging Drugs
Pamrevlumab: FibroGen
FibroGen is developing Pamrevlumab (also known as FG-3019), an intravenously administered, first-in-class, fully-humanized monoclonal antibody that inhibits the activity of connective tissue growth factor activity, or CTGF, a critical mediator in the progression of fibrosis and related serious diseases.
PRM-151 (RG6354): Hoffmann-La Roche Ltd
PRM-151 (RG6354) is an intravenously administered, recombinant human serum amyloid P/pentraxin 2 protein (PTX2) that is being developed by Roche. Pentraxin 2 is an endogenous protein - present in humans - that regulates the fibrosis response. It helps the immune system to naturally reverse and turn off the fibrosis process that may be caused due to excessive secretion of collagen, cellular growth, and differentiation. RG6354 works by healing the fibrotic tissue, unlike other therapies, which tend to direct a single target inhibition.
Tyvaso (inhaled treprostinil): United Therapeutics
Tyvaso (treprostinil) is a prostacyclin mimetic approved for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The company is currently evaluating Tyvaso in an ongoing worldwide Phase III clinical trial named TETON 1 for the treatment of patients with IPF.
Products detail in the report…
List of products to be continued in the report…
Idiopathic pulmonary fibrosis (IPF) is a lung disorder with scarring of the lungs from an unknown cause. It is one of the most aggressive forms of idiopathic interstitial pneumonia (IIPs). The majority of patients are male, and the risk of IPF for someone aged 75 years is eight times that of someone aged 45-54 years. It is reported that without treatment, the median survival in patients with IPF is 2-4 years after diagnosis.
There are two antifibrotic agents approved for use in IPF. These are pirfenidone and nintedanib (tyrosine kinase inhibitors). Both drugs are known to slow the disease progression but not significantly impact mortality. For this reason, early initiation of therapy is recommended. Further studies have also decreased exacerbations of IPF with these drugs. Serial monitoring of liver function tests is recommended while on either drug. The most common side effect reported with nintedanib is diarrhea and pirfenidone rash, photosensitivity, and gastrointestinal discomfort. Gastrointestinal side effects are the most common reason for discontinuing both drugs. According to survey reports, most European physicians are either unaware of these antifibrotic drugs or believe in the wait and watch strategies during the progression of IPF. It was found that only 71% of mild IPF diagnosed patients, 41% of moderate IPF diagnosed patients, and around 60% of severe IPF diagnosed patients receive treatment in European counties.
Over the years, some drugs have been investigated to treat IPF cases. Drug molecules such as Pamrevlumab, PRM-151, and Inhaled Treprostinil are in Phase III and have shown positive results in previous clinical studies. In addition to this, some candidates are in Phase II and early stages.
Key Findings
This section provides the total Idiopathic Pulmonary Fibrosis market size and market size by therapies in the United States.
The total Idiopathic Pulmonary Fibrosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total Idiopathic Pulmonary Fibrosis market size and market size by therapies in Japan are provided.
This section focuses on the rate of uptake of the potential drugs recently launched in the Idiopathic Pulmonary Fibrosis market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Idiopathic Pulmonary Fibrosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Idiopathic Pulmonary Fibrosis Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stages also analyze key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Idiopathic Pulmonary Fibrosis emerging therapies.
Reimbursement Scenario in Idiopathic Pulmonary Fibrosis
OFEV and ESBRIET have Medicare and commercial coverage on national plans. For OFEV there are programs designed to help with the out-of-pocket cost for patients with IPF in the United States. These programs include The OFEV Commercial Copay Program, The BI Cares Foundation, and some third-party financial assistance. While for ESBRIET programs such as ESBRIET Co-pay Program, Genentech Patient Foundation, and support from independent co-pay assistance foundations are available.
Competitive Intelligence Analysis
We perform competitively and market Intelligence analysis of the Idiopathic Pulmonary Fibrosis market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Key Questions
Market Insights:
Epidemiology Insights:
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies: